Loading…
Weigao Group's orthopedic implant subsidiary, making joint-replacement, spine and trauma devices.
Weigao Group's orthopedic implant subsidiary, making joint-replacement, spine and trauma devices.
Sells implants to hospitals mostly through distributors. China's government bulk-purchase tenders for joint, trauma and spine implants have set prices for much of the market, so winning tender volume matters more than list price. It is a listed subsidiary of Weigao Group, whose hospital relationships it draws on.
In one line: A Chinese Zimmer Biomet/Stryker Orthopaedics.
Moat: narrow (regulatory licence, installed base). Weigao Group's hospital distribution scale supports an established device franchise.
Headquarters: Weihai, Shandong, China · Employees: 1,988
Size Shandong Weigao Orthopaedic Device (688161.SS) is a China Health Care company (Medical Specialties) with a market value of $1.24B, the 1919th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥20.80 on 6 Nov 2026.
Performance Over six months the shares fell 25.3%, against -5.5% for the median peer and -16.4% for the China market (cap-weighted) — 4th lowest of 20 in its peer set.
Growth Revenue fell 6.0% over the last twelve months (peer median +14.2%); the operating margin is 17.7% (peer median 5.6%).
Valuation It trades at 27.0× forward earnings against a peer median of 29.4× (7th cheapest of 13).
Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is -4%, so the hurdle is +16 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.2 points above its cost of capital (7.8% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.39B | CN¥1.51B | CN¥1.44B | CN¥1.27B | CN¥2.03B |
| Revenue growth | — | +5% | +14% | -38% | — |
| Gross profit | CN¥949M | CN¥936M | CN¥916M | CN¥810M | CN¥1.52B |
| EBITDA | n/a | CN¥384M | CN¥327M | CN¥175M | CN¥726M |
| Net income | CN¥239M | CN¥269M | CN¥224M | CN¥112M | CN¥601M |
| Free cash flow | CN¥253M | CN¥421M | CN¥283M | CN¥100M | CN¥419M |
| Capital expenditure | CN¥43.0M | CN¥27.1M | CN¥24.3M | CN¥43.0M | CN¥116M |
| Total debt | CN¥77.2M | CN¥80.8M | CN¥79.1M | CN¥96.4M | CN¥55.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shandong Weigao Orthopaedic Device 688161.SS | $1.24B | -25% | -6% | 18% | 27.0× | 12.7% |
| Zimmer Biomet ZBH | $20.1B | +29% | +7% | 16% | 12.0× | -1.4% |
| Stryker SYK | $124B | +14% | +8% | 25% | 20.4× | 10.6% |
| Double Medical Technology 002901.SZ | $2.56B | -3% | +13% | 26% | 25.9× | 8.3% |
| Beijing Chunlizhengda Medical Instruments 1858.HK | $671M | -27% | -9% | 31% | 9.2× | -8.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688161.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.7% | +1.2% | 8th lowest of 21 |
| 6-month return | -25.3% | -5.5% | 4th lowest of 20 |
| Distance from 52-week high | -36.4% | -33.2% | 10th lowest of 21 |
| Revenue growth (TTM) | -6.0% | +14.2% | 3rd lowest of 19 |
| Operating margin | 17.7% | 5.6% | 7th highest of 19 |
| Forward P/E | 27.0× | 29.4× | 7th cheapest of 13 |
| Growth the price implies (Req g, 7 yrs) | 12.7% | 8.3% | 3rd most demanding of 9 |
| Growth delivered (Del g) | -3.5% | +10.1% | lowest of 9 |
| Hurdle (Req g minus delivered) | +16.3 pp | -4.8 pp | 2nd most demanding of 9 |
| ROIC minus cost of capital | +0.2 pp | -2.5 pp | 9th highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shandong Weigao Orthopaedic Device 688161.SS | China | $1.24B | -25% | -6% | 18% | 27.0× | 12.7% | -3.5% |
| CLASSYS 214150.KS | South Korea | $1.25B | -54% | +25% | 46% | 12.1× | -8.7% | +34.5% |
| Guangzhou Hexin Instrument 688622.SS | China | $1.26B | +58% | -29% | -74% | n/a | n/a | n/a |
| STAAR Surgical STAA | United States | $1.26B | -6% | +51% | 18% | 45.8× | n/a | n/a |
| Eyebright Medical Technology (Beijing) 688050.SS | China | $1.27B | -15% | +21% | 16% | 25.2× | 10.8% | +40.3% |
| Alpha Tau Medical DRTS | United States | $1.27B | +61% | n/a | n/a | n/a | n/a | n/a |
| PROCEPT BioRobotics PRCT | United States | $1.18B | -19% | +23% | -34% | n/a | n/a | n/a |
| Tandem Diabetes Care TNDM | United States | $1.18B | +9% | +4% | -4% | n/a | n/a | n/a |
| Shenzhen Edge Medical 2675.HK | Hong Kong | $1.31B | -51% | +132% | 2% | 130.1× | n/a | n/a |
| Inno Laser Technology 301021.SZ | China | $1.16B | -18% | +17% | 9% | n/a | 53.9% | +8.6% |
| Alphatec ATEC | United States | $1.15B | -1% | +15% | -3% | 15.0× | n/a | n/a |
| Mingyue Optical Lens 301101.SZ | China | $1.14B | +6% | +14% | 25% | 33.7× | 10.0% | +8.8% |
| Sansure Biotech 688289.SS | China | $1.36B | -8% | -1% | 1% | 39.0× | n/a | n/a |
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | +1% | -4% | 36% | 18.2× | 1.5% | +9.9% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.11B | -27% | -11% | -33% | n/a | n/a | n/a |
| IRadimed IRMD | United States | $1.10B | 0% | +11% | 32% | 36.0× | 19.1% | +21.5% |
| Amoy Diagnostics 300685.SZ | China | $1.10B | -14% | +7% | 34% | 20.9× | 6.5% | +10.3% |
| Freenome FRNM | United States | $1.09B | n/a | n/a | n/a | n/a | n/a | n/a |
| SI-BONE SIBN | United States | $1.09B | +98% | +14% | -8% | n/a | n/a | n/a |
| PHC 6523.T | Japan | $1.09B | +36% | +3% | 7% | 7.9× | -2.3% | +3.6% |
| Sonoscape Medical 300633.SZ | China | $1.42B | -8% | +18% | 4% | 36.8× | n/a | n/a |